Navigation Links
Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation
Date:4/21/2009

tive tax rate for fiscal 2010 of approximately 21.5%

* Diluted shares outstanding will average approximately 303,000,000 for the fiscal year ending March 31, 2010.

Howard Solomon, Chairman and Chief Executive Officer of Forest, said: "Fiscal 2009 was a year of solid performance from our key promoted products, including a stronger than anticipated first year performance from Bystolic. During the year we were granted two important marketing approvals from the FDA. Firstly, Savella was approved for the management of fibromyalgia, following a first cycle review. Savella is a valuable new treatment option for patients with the chronic and often debilitating condition of fibromyalgia. Also, Lexapro received approval for the important additional indication for the acute and maintenance treatment of major depressive disorder in adolescents, 12 to 17 years of age. Further, we received a patent term extension for Namenda which extends its exclusivity to April, 2015. Along with the steady progress of our product pipeline, we were also very pleased to announce the addition of two late-stage products. We partnered with the Phenomix Corporation to develop and commercialize dutogliptin, for the treatment of Type 2 diabetes mellitus and with Pierre Fabre Medicament to develop and commercialize levomilnacipran for the treatment of depression.

In fiscal 2010, we will continue to advance our product development pipeline, which includes six products in Phase III development and two products currently in Phase II-b development that we expect to progress into Phase III later this year. Very shortly we will begin additional Phase III studies of aclidinium, for the treatment of COPD, to provide further support for higher and/or more frequent dosage regimens which we expect will significantly increase the potential clinical utility of this novel compound. In the coming months we expect to file a sNDA for Bystolic for the treatment
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
5. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
6. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
8. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
9. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
10. Old-Growth Forests Dying Off in U.S. West
11. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... February 28, 2015 The MCA Youth ... Malaysia into one platform and gears towards the goal ... A series of group talks in smaller groups will ... Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social and ... awareness of Malaysian youths. , Young adults ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... 2015 March—also known as National ... remind ourselves and others that suspected head injuries, ... Specialists (ANS). , Concussions are a form of ... of TBIs. There are 1.6-3.8 million sports-related concussions ... but it is a brain injury. Many athletes ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... R.I. [Brown University] Despite evidence that feeding tubes ... for elderly patients with advanced dementia, their frequency of ... of family members finds that discussions surrounding the decision ... Advanced dementia is a terminal illness that often affects ...
... People with dementia may soon have improved oral hygiene ... four-year grant to Rita A. Jablonski, assistant professor of ... disease have all been linked to poor oral hygiene. ... for because they often are no longer able to ...
... of disease progression and response to chemotherapy in breast ... patients, but do not always agree in their predictions ... In recent years, several genomic tests have ... Dr Catherine Kelly from Mater Misericordiae University Hospital, Dublin, ...
... In a rare and medically remarkable operation, a multi-disciplinary team ... Arthur G. James Cancer Hospital and Richard J. Solove ... and pelvis of a cancer patient, and used the healthy, ... connection between his spine and remaining right pelvis to support ...
... May 4 (HealthDay News) -- U.S. health officials issued ... of liquid over-the-counter drug products that are measured and ... droppers. The U.S. Food and Drug Administration developed ... of overdoses when using liquid over-the-counter (OTC) pain relievers, ...
... , WEDNESDAY, May 4 (HealthDay News) -- A ... group of congenital heart defects that cause a major proportion ... unclear how these cardiac defects -- all malformations of the ... suggests a genetic component may play a role. "It ...
Cached Medicine News:Health News:Families need to know more about feeding tubes for elderly dementia patients 2Health News:Breast cancer multi-gene tests compared 2Health News:Breast cancer multi-gene tests compared 3Health News:Ohio State surgeons rebuild pelvis of cancer patient 2Health News:Ohio State surgeons rebuild pelvis of cancer patient 3Health News:FDA Issues Guidelines for Liquid OTC Medicines 2Health News:New Gene Linked to Congenital Heart Defects 2
(Date:2/27/2015)... , February 27, 2015 ... sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) ... -     ... die ein neuartiges Herzüberwachungssystem für Patienten mit ... bekannt, dass sie ein Finanzierungsvorhaben über 5 ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 /PRNewswire/ ... are increasing in applications as their effectiveness ... firm Kalorama Information.  Kalorama Information says that ... is the most powerful tool in proteomic ... spec; MS) through its traditional techniques has ...
(Date:2/26/2015)... , Feb. 26, 2015  AbbVie (NYSE: ... abstracts of studies in its neuroscience and oncology ... the 67 th American Academy of Neurology ... , from April 18-25. The accepted abstracts feature ... in addition to investigational treatments in AbbVie,s pipeline. ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced that updated ... of the triplet combination of TELCYTA(R),(canfosfamide HCl, ... the 98th annual meeting of the American ... Preclinical studies of,cellular and molecular correlates of ...
... WIRE)--Apr 11, 2007 - Cyclacel,Pharmaceuticals, Inc. (Nasdaq: ... the company will present results of two,preclinical ... advanced drug candidates in clinical development. The ... during the upcoming,Annual Meeting of the American ...
Cached Medicine Technology:Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 2Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 3Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 4
... 3085 SP Surgical Table combines innovation and ... weighing up to 1,000 lbs. You can ... both normal and reverse orientation and have ... other patients.,The Amsco 3085 SP Table offers ...
... important part in our daily lives. But ... can cause severe handicaps. A decisive consideration ... was to produce a reconstructed joint function ... nearly possible.,The cementless RM Finger System has ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: